Myelodysplastic Syndromes

Latest News
October 18th 2024

Phase 1b/2 Study Supports Use of Telaglenastat and Azacytidine in Advanced MDS

October 11th 2024

In Lower-Risk MDS, Genomic Dynamics Heighten Likelihood of Treatment

October 4th 2024

JAK Inhibitors Show Promise in Concurrent Myeloid Disorders, IADs

September 21st 2024

Low Hemoglobin, IDH2 Mutation Indicative of Poor Survival in MDS

September 13th 2024

Celiac Disease Associated With Varying Risks for Cancers

Video Interviews
View All
March 17th 2024

Dr Jennifer Vaughn: We Can Provide Aggressive, Effective Treatment, but Help Patients Maintain Quality of Life

February 3rd 2023

Treatment Patterns in the Management of MDS

January 27th 2023

Treatment Paradigm in Lower-Risk MDS (LR-MDS) Patients

January 20th 2023

TP53 Mutation and Its Impact on Patient Outcomes in MDS

December 29th 2022

Age Considerations for Findings on Venetoclax Combined With CLIA for AML, High-Risk MDS

December 23rd 2022

Dr Patrick Reville: How Patients With MDS, MPAL Responded to Venetoclax With CLIA

December 21st 2022

ASCERTAIN Trial Overview

December 16th 2022

Dr Patrick Reville Covers Study Results on Venetoclax Combined With CLIA

November 15th 2022

Key Considerations for Overall MDS Treatment Management

November 15th 2022

Future Treatment of MDS

More News

Telomeres act as protective caps on the ends of chromosomes | image credit: Anastasiia - stock.adobe.com
September 3rd 2024

RIOK2 Regulates Telomerase Subunits to Prevent Telomere Shortening

Gwen Mergian
New research linking telomere shortening to myelodysplastic syndromes (MDS) offers substantial therapeutic implications for affected patients and MDS research.
Patient takes medicine | Image Credit: © Seventyfour - stock.adobe.com
August 25th 2024

High Patient Satisfaction Seen With Oral DEC-C in Myelodysplastic Syndromes

Kimberly Rath, PharmD
Patients with myelodysplastic syndromes report high satisfaction with oral decitabine/cedazuridine (DEC-C) vs traditional intravenous or subcutaneous hypomethylating agents.
red blood cells | Image Credit: kolonko-stock.adobe.com
August 23rd 2024

Clinical, Economic Outcomes Associated With Alloimmunization in MDS

AJMC Contributor
The researchers found inferior outcomes and higher accrued costs associated with alloimmunization in patients with myelodysplastic syndromes (MDS), a disease that relies on transfusion of red blood cells.
Guidelines folder | Image Credit: tashatuvango-stock.adobe.com
August 16th 2024

New Guidelines Clarify MDS Classification, Highlight Diagnostic Nuances

Gayle Turim Dickstein
Authors acknowledge that both the 2022 World Health Organization and International Consensus Classification myelodysplastic syndrome criteria sets have value, while sorting out their similarities and differences.
science and teamwork | Image Credit: Coetzee peopleimages-stock.adobe.com
August 9th 2024

Lab Technology Advances Detection of MDS

Gayle Turim Dickstein
More and more hematology factors and parameters can be analyzed with advanced equipment to better pinpoint which patients might have myelodysplastic syndromes (MDS)—but the differences in leading makers’ systems can be tricky to maneuver.
MDS wooden blocks | Image Credit: Sviatlana - stock.adobe.com
August 2nd 2024

Report: ESAs Largely Ineffective in Lower-Risk MDS

Jared Kaltwasser
Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs).
stem cell transplant | Image Credit: Vadim-stock.adobe.com.jpeg
July 28th 2024

HCT Outcomes Show Improvement With Posttransplant Cyclophosphamide

Karen Jacobson-Sive
Post–hematopoietic cell transplantation (HCT) prophylaxis using cyclophosphamide to stave off graft-vs-host disease had positive results compared with calcineurin inhibitor–based prophylaxis, regardless of whether the patient had a matched or unmatched donor.
MDS test | Image Credit: Saiful52-stock.adobe.com
July 22nd 2024

Study Identifies Risk Factors for Progression From Low-Risk MDS

Jared Kaltwasser
The findings show most patients with low-risk myelodysplastic syndrome (MDS) will die before progression.
transfusion setup | Image Credit: Parilov-stock.adobe.com
July 15th 2024

Sponsor Terminates MATTERHORN Trial of Roxadustat for Low-Risk MDS

Jared Kaltwasser
Patients with myelodysplastic syndrome (MDS) in the treatment arm were more likely to achieve transfusion independence, but the difference vs placebo was not statistically significant.
Telehealth solutions | Image Credit: Dmitry - stock.adobe.com
July 10th 2024

Telehealth Can Drive More Meaningful Serious Illness Conversations in MDS, AML

AJMC Contributor
Researchers collected feedback from 20 clinicians implementing a telehealth serious illness conversation (SIC) with their patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Giving bad news | Image Credit: engagestock-stock.adobe.com
July 3rd 2024

VEXAS Syndrome Often Misdiagnosed as Pyoderma Gangrenosum

AJMC Contributor
In a recently published systematic review, researchers determined that VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome typically presents in men, with atypical morphology and with systemic symptoms.
MDS panel | Image Credit: MdBabul-stock.adobe.com
June 27th 2024

Clinicians, Caregivers, Patients: MDS Treatment Preferences Explored

Kimberly Rath, PharmD
Study findings provide new tools to assess treatment preferences when using hypomethylating agents in myelodysplastic syndromes (MDS).
myelodysplastic disease diagnosis | Image Credit: ibreakstock-stock.adobe.com
June 19th 2024

How Inflammation Factors May Influence Lower-Risk MDS

Gayle Turim Dickstein
Determining the roles that various inflammatory markers and pathways play in lower-risk myelodysplastic syndromes (MDS) could lead to therapies that keep disease progression at bay.
Gut microbiome | Image Credit: © sdecoret - stock.adobe.com
June 13th 2024

Gut Microbiota Found to Influence MDS Risk Through Immune Cells

Kimberly Rath, PharmD
Researchers have identified a causal link between gut microbiota and myelodysplastic syndrome (MDS) risk, mediated by certain key immune cell phenotypes.
Scientific investigation | Image Credit: makibestphoto-stock.adobe.com
June 5th 2024

Consortium: PROs Have Key Role in MDS Trials

Jared Kaltwasser
The coalition said, however, that patient-reported outcomes (PROs) in the myelodysplastic syndrome (MDS) space will be most meaningful if they are collected rigorously and if the data are transparent.
MDS Panel | Image Credit: MdBabul-stock.adobe.com
May 22nd 2024

Key Factors Significantly Associated With ESA Response in Lower-Risk MDS

Luke Halpern
Hemoglobin levels, transfusion independence, and low serum erythropoietin levels were all deemed to have a statistically significant relationship with erythropoiesis-stimulating agent (ESA) response.
MDS blood test | Image Credit: MdBabul-stock.adobe.com
May 16th 2024

Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS

Kimberly Rath, PharmD
Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
MDS graphic | Image Credit: MdBabul-stock.adobe.com
May 8th 2024

Diagnostic Oversights Limit Luspatercept Benefits in MDS

Gayle Turim Dickstein
Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Medicine doctor hold icon health and electronic medical record on interface. Digital healthcare and network connection on hologram virtual screen, insurance. medical technology and network concept | Image Credit: © ipopba - stock.adobe.com
April 30th 2024

Machine Learning and Neural Network Can Be Effective Diagnostic Tools in MDS, Study Finds

Jared Kaltwasser
The investigators said their new system makes it possible for researchers to leverage artificial intelligence even if they do not have expertise working with advanced software.
MDS graphic | Image Credit: Sviatlana - stock.adobe.com
April 15th 2024

Improving Cancer Care: The Role of Oral Hypomethylating Agents and Education

Jared Kaltwasser
Investigators say oral formulations of hypomethylating agents could be a significant advancement for people with myelodysplastic syndromes and acute myeloid leukemia.
Myelodysplastic syndrome written on a clipboard | Image Credit: syahrir - stock.adobe.com
April 11th 2024

TP53-Mutated MDS/AML Posttransplant Treatment Gaps

Luke Halpern
The rate of relapse among patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) was similar among those who underwent allogeneic hematopoietic stem cell transplant vs those who did not.
Laptop with words Myelodysplastic Syndrome | Image Credit:Yurii Kibalnik - stock.adobe.com
April 4th 2024

Heterogeneous Practices Common in Treatment, Monitoring of Patients With Myelodysplastic Syndrome With Del(5q)

Luke Halpern
This study builds on previous evidence for lenalidomide-induced selective advantage for TP53-mutant clones.
Concept of Meylodysplastic Syndrome | Image Credit: syahrir - stock.adobe.com
March 26th 2024

Venetoclax Resistance in Patients With MDS Explained in New Study

Jared Kaltwasser
The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes.
MDS Myelodysplastic syndrome | Image Credit: © Sviatlana - stock.adobe.com.jpeg
March 16th 2024

Luspatercept Benefits Transfusion-Dependent Patients With MDS and Anemia in Real-World Study

Jared Kaltwasser
The report found the therapy boosted rates of transfusion independence, particularly among patients who had a low baseline transfusion rate.
Bone marrow from MDS | Image credit: tonaquatic - stock.adobe.com
March 9th 2024

Venetoclax/Azacitidine Shows Promise for Relapse Prevention in High-Risk MDS and AML

Luke Halpern
Venetoclax and azacitidine was found safe, but further randomized trials are needed to determine the full extent of the combination’s efficacy in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Myelodysplastic disease diagnosis | Image credit: ibreakstock - stock.adobe.com
February 28th 2024

Gene Mutations Linked to Adverse Outcomes in AML/MDS

Gwen Mergian
A rare mutation on the BCL6-corepressor gene correlated with worse overall survival in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, allogenic stem cell transplant improved survival in this population.
Blood sample for MDS test | Image Credit: MdBabul - stock.adobe.com
February 22nd 2024

Study Describes Characteristics, Outcomes of Patients With Low-Risk MDS

Jared Kaltwasser
Investigators say a better understanding of risk factors and categories can help personalize care for patients living with myelodysplastic syndrome (MDS).
Letter blocks of MDS | Image credit: Sviatlana-stock.adobe.com
February 22nd 2024

Venetoclax Plus HMA Therapy Shows Encouraging Results in Higher-Risk MDS/CMML

Laura Joszt, MA
Results of a phase 1/2 trial show encouraging outcomes for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) treated with the fully oral regimen of venetoclax and decitabine plus cedazuridine.
Businessman presenting concept about research innovation and experiments | Image credit: NicoElNino - stock.adobe.com
February 6th 2024

Signaling Pathways in MDS a Fruitful Area for Research, Drug Development

Jared Kaltwasser
A review of recent research into myelodysplastic syndromes (MDS) shows a range of potential therapeutic targets.
Psychology and mental health, a female patient feeling nervous in a clinic for support | Image credit: KApeopleimages - stock.adobe.com
February 2nd 2024

Uncertainty, Coping Strategies Common Among Patients With AML, High-Risk MDS

Luke Halpern
Patients with comorbid acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) expressed a desire to discuss treatment options and maintain normalcy; they were not willing to have conversations involving their prognosis and future.
12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo